RxDoctor Payments Data

William Vonah, MD

Internal Medicine · Carlisle, PANPI 1912993007

Payments from drug & device makers

$204in general payments, 2019–2025

Across 14 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$47
  • Genentech USA, Inc.$27
  • Novo Nordisk$24
  • Pacira Therapeutics, Inc.$20
  • Amgen$18
  • Lilly USA, LLC$17
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$204100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$204 in reported general payments places this provider in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,305
Medicare patients
385
Services billed
1,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$135,667
MounjaroTirzepatide118$125,634
EliquisApixaban119$110,094
XareltoRivaroxaban70$59,380
JanuviaSitagliptin Phosphate35$43,615
FarxigaDapagliflozin Propanediol29$33,200
TrulicityDulaglutide25$29,382
JardianceEmpagliflozin18$24,972
WegovySemaglutide12$15,575
MyrbetriqMirabegron24$14,593
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,739
JanumetSitagliptin Phos/Metformin Hcl13$10,275
Combivent RespimatIpratropium/Albuterol Sulfate16$9,220
Tresiba Flextouch U-100Insulin Degludec18$8,974
Breo ElliptaFluticasone/Vilanterol16$8,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$17$155,016143 claims
Novo NordiskOzempic, Wegovy$24$151,242132 claims
PfizerEliquis$47$110,094119 claims
Johnson & JohnsonXarelto$13$59,38070 claims
MerckJanuvia, Janumet$13$53,89048 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$11$40,23546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Carlisle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →